Induction of growth hormone release by Pueraria thunbergiana BENTH

Tectorigenin: A Review of Its Sources, Pharmacology, Toxicity, and Pharmacokinetics

Tectorigenin is a well-known natural flavonoid aglycone and an active component that exists in numerous plants. Growing evidence suggests that tectorigenin has multiple pharmacological effects, such as anticancer, antidiabetic, hepatoprotective, anti-inflammatory, antioxidative, antimicrobial, cardioprotective, and neuroprotective. These pharmacological properties provide the basis for the treatment of many kinds of illnesses, including several types of cancer, diabetes, hepatic fibrosis, osteoarthritis, Alzheimer's disease, etc. The purpose of this paper is to provide a comprehensive summary and review of the sources, extraction and synthesis, pharmacological effects, toxicity, pharmacokinetics, and delivery strategy aspects of tectorigenin. Tectorigenin may exert certain cytotoxicity, which is related to the administration time and concentration. Pharmacokinetic studies have demonstrated that the main metabolic pathways in rats for tectorigenin are glucuronidation, sulfation, demethylation and methoxylation, but that it exhibits poor bioavailability. From our perspective, further research on tectorigenin should cover: exploring the pharmacological targets and mechanisms of action; finding an appropriate concentration to balance pharmacological effects and toxicity; attempting diversified delivery strategies to improve the bioavailability; and structural modification to obtain tectorigenin derivatives with higher pharmacological activity.

Evaluation of in vivo estrogenic potency of natural estrogen-active chemical, puerarin, on pituitary function in gonadectomized female rats

AIMS

Previous research has revealed that puerarin, the major phytoestrogen in tuberous roots of Pueraria lobata and Pueraria mirifica, acts as a selective estrogen receptor modulator that displays predominantly estrogenic potential for health benefit. However, little is known about the estrogenic potency of puerarin in pituitary, especially in the rat model of postmenopausal females.

MAIN METHODS

Plasma prolactin and growth hormone levels as well as mRNA expression levels of pituitary estrogen-regulated genes, such as estrogen receptor (ER) subtypes alpha (ERα) and beta (ERβ), truncated ER product-1 (TERP-1) and -2 (TERP-2) and gonadotropin alpha subunit, were examined using radioimmunoassay and TaqMan® real-time PCR, respectively. The effects were compared with the potent ER agonist, 17β-estradiol-3-benzoate (E2B), and both substances were supplemented at low and high doses, i.e., 0.6 or 3g puerarin and 0.0043 or 0.0173g E2B per kilogram of phytoestrogens-free rat chow, and applied to ovariectomized rats (five groups; 11-12 rats per group) for 12weeks.

KEY FINDINGS

Puerarin possessed weak E2B-like activities on pituitary function by acting as ERβ and TERP-1/-2 agonists, which resulted in the downregulation and upregulation of ERβ and TERP-1/-2 mRNA expressions, respectively, and elevation of growth hormone levels. There were trends of decreased levels of alpha subunit mRNA transcripts and increased levels of prolactin in puerarin-treated rats as observed in E2B-treated animals.

SIGNIFICANCE

This is the first report in ovariectomized rats the effects of puerarin on somatotropes and pituitary estrogen-responsive mRNA expressions, which are very weakly estrogenic by acting through ERβ- and TERP-1/-2 mediated pathways.

An evidence-based systematic review of kudzu (Pueraria lobata) by the Natural Standard Research Collaboration

An evidence-based systematic review of kudzu (Pueraria lobata) by the Natural Standard Research Collaboration consolidates the safety and efficacy data available in the scientific literature using a validated, reproducible grading rationale. This article includes written and statistical analysis of clinical trials, plus a compilation of expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.

Clinical study to evaluate the Brinhaniya effect of Vidarikandadi Yog to enhance the sport performance in children

Background:

Sport science studies applications of scientific principles and techniques with the aim of improving sports performance.

Objective:

Present research work was carried out with the aim to enhance the sport performance of children.

Materials and Methods:

Randomized double blind placebo controlled study was conducted in children involved in sports to assess the efficacy of trial drug “Vidarikandadi Yog”. Total of 72 healthy students were selected for the study after screening 412 students. Out of them, 60 students completed the study. The students were randomly divided into two groups. Group A (Vidarikandadi Yog) comprising of 38 and Group B (placebo) of 34 students. The trial drug “Vidarikandadi Yog” was given in the dose of 200 mg/kg/day in two divided doses for 2 months with milk and follow up was conducted fortnightly.

Results:

The study revealed the statistically significant results for weight and chest circumference, whereas highly significant results were obtained for muscular strength and endurance assessment parameters (Push-up Test, Sit-up Test, and Hand Grip Strength Test). Change in Ruler Drop Test was not significant. Results were significant for cardio-respiratory parameters (Resting Heart Rate, Resting Respiratory Rate, and Harvard Step Test).

Conclusion:

Vidarikandadi Yog is a potential drug for enhancing the sport performance due to its Brinhaneeya effect.

Induction of growth hormone release by glycyrrhizae radix on rat

Induction of growth hormone (GH) by Glycyrrhizae Radix (GR), one of the most popular herbal medicine, and its major ingredients were studied in rat pituitary cells in vitro and in vivo assay. The MeOH extract and the n-hexane (HX) fraction of GR induced rat GH (rGH) release up to 1.89 times (0.34 +/- 0.04 nM) and 4.59 times (0.83 +/- 0.03 nM), compared to the basal level (p < 0.05). Among many ingredients isolated and purified from GR both glycyrrhetinic acid and glycyrrhizin induced significantly rGH release compared to the control (p < 0.05). After an intravenous injection of rat growth hormone releasing hormone (rGHRH) (10 microg/kg) as positive control, in SD rats, Tmax of plasma rGH level was 10 min, C(max) was 3.84 +/- 0.01 nM (n = 3), and enhanced plasma rGH level returned to the baseline in 90 min. Both AUC(0-90) (area under the curve) of plasma rGH level after HX fraction and that after rGHRH administration were increased significantly from the basal level, respectively (p < 0.01). In conclusions, HX fraction is the most active fraction of MeOH extract of GR in rGH induction.